ArticleBMC medical imaging2026
MRI-based radiomics interpretable model predicts microsatellite instability status in endometrioid adenocarcinoma.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo develop and validate a multiparametric MRI-based radiomics model for noninvasive preoperative prediction of microsatellite instability (MSI) in patients with endometrioid adenocarcinoma (EC), and to improve model interpretability with SHapley Additive exPlanations (SHAP) analysis.
methodsWe enrolled 241 patients with pathologically confirmed EC and divided them into training (n = 193) and test (n = 48) cohorts at an 8:2 ratio. Radiomic features were extracted from T2-weighted imaging (T2WI), apparent diffusion coefficient (ADC), and late-phase T1-weighted contrast-enhanced (T1CE) sequences. Feature screening was performed sequentially via intraclass correlation coefficient (ICC) filtering, Pearson collinearity elimination, and 10-fold cross-validated least absolute shrinkage and selection operator (LASSO) regression. Five machine learning models were constructed and evaluated via area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity. The optimal model was validated using decision curve analysis (DCA), and SHAP analysis was applied to interpret feature contributions.
resultsThe MSI rate was 29% (70/241). Four features were retained after selection. The XGBoost model achieved the best performance (training AUC = 0.983, test AUC = 0.870), with test set accuracy of 0.812, sensitivity of 0.929, and specificity of 0.765. DCA confirmed clinical utility, SHAP analysis identified T2WI-GLSZM GrayLevelVariance as the most impactful feature and visualized the differences in feature contributions between MSI and MSS patients at the individual level, clarifying the model's decision-making logic.
conclusionThe multiparametric MRI-based radiomics model enables noninvasive prediction of MSI in EC, potentially guiding personalized immunotherapy selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.